SARS-CoV-2 Transmission in Belgian French-Speaking Primary Schools: An Epidemiological Pilot Study.


Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
06 10 2022
Historique:
received: 31 08 2022
revised: 27 09 2022
accepted: 28 09 2022
entrez: 27 10 2022
pubmed: 28 10 2022
medline: 29 10 2022
Statut: epublish

Résumé

Schools have been a point of attention during the pandemic, and their closure one of the mitigating measures taken. A better understanding of the dynamics of the transmission of SARS-CoV-2 in elementary education is essential to advise decisionmakers. We conducted an uncontrolled non-interventional prospective study in Belgian French-speaking schools to describe the role of attending asymptomatic children and school staff in the spread of COVID-19 and to estimate the transmission to others. Each participant from selected schools was tested for SARS-CoV-2 using a polymerase chain reaction (PCR) analysis on saliva sample, on a weekly basis, during six consecutive visits. In accordance with recommendations in force at the time, symptomatic individuals were excluded from school, but per the study protocol, being that participants were blinded to PCR results, asymptomatic participants were maintained at school. Among 11 selected schools, 932 pupils and 242 school staff were included between January and May 2021. Overall, 6449 saliva samples were collected, of which 44 came back positive. Most positive samples came from isolated cases. We observed that asymptomatic positive children remaining at school did not lead to increasing numbers of cases or clusters. However, we conducted our study during a period of low prevalence in Belgium. It would be interesting to conduct the same analysis during a high prevalence period.

Identifiants

pubmed: 36298754
pii: v14102199
doi: 10.3390/v14102199
pmc: PMC9612207
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Nucleic Acids Res. 2019 Jul 2;47(W1):W260-W265
pubmed: 31028399
BMJ Open. 2022 Feb 2;12(2):e054292
pubmed: 35110320
BMJ Open. 2013 Feb 26;3(2):
pubmed: 23447463
J Glob Health. 2020 Dec;10(2):021104
pubmed: 33437465
Science. 2021 Sep 17;373(6561):1294-1295
pubmed: 34529478
J Glob Health. 2020 Dec;10(2):021101
pubmed: 33312511
JAMA Netw Open. 2021 Aug 2;4(8):e2122240
pubmed: 34448865
Diagnostics (Basel). 2022 Jan 11;12(1):
pubmed: 35054329
Pediatr Infect Dis J. 2022 Apr 1;41(4):e172-e174
pubmed: 35315825
Commun Med (Lond). 2022 Jan 10;2:1
pubmed: 35603280
Arch Dis Child. 2021 Nov;106(11):1039-1040
pubmed: 33250448
JAMA Netw Open. 2020 Dec 1;3(12):e2031756
pubmed: 33315116
JAMA Netw Open. 2021 Oct 1;4(10):e2128757
pubmed: 34636913
Arch Dis Child. 2021 Feb;106(2):111-113
pubmed: 32747375
Proc Natl Acad Sci U S A. 2021 Jun 22;118(25):
pubmed: 34103391
PLoS One. 2021 Mar 31;16(3):e0248336
pubmed: 33788848
J Clin Microbiol. 2021 Mar 19;59(4):
pubmed: 33514627
BMJ. 2022 Jan 7;376:o21
pubmed: 34996758
Lancet Infect Dis. 2021 Mar;21(3):344-353
pubmed: 33306981
Lancet Child Adolesc Health. 2021 Jun;5(6):417-427
pubmed: 33740430
JAMA Netw Open. 2021 Apr 1;4(4):e217097
pubmed: 33890990
JAMA. 2021 May 25;325(20):2112-2113
pubmed: 33861316
Front Pediatr. 2021 Apr 09;9:613292
pubmed: 33898355
Transp Res Interdiscip Perspect. 2021 Mar;9:100290
pubmed: 33763644
JAMA Netw Open. 2022 Feb 1;5(2):e2147827
pubmed: 35157056
J Clin Virol. 2020 Jul;128:104413
pubmed: 32403010
PLoS One. 2022 Feb 25;17(2):e0264516
pubmed: 35213651
Eur J Pediatr. 2022 Feb;181(2):571-578
pubmed: 34455523

Auteurs

Julie Frère (J)

Pediatric Infectious Diseases, Pediatric Department, CHU Liège, 4000 Liège, Belgium.

Olga Chatzis (O)

Pediatric Infectious Diseases, Specialized Pediatric Service, Pediatric Department, Cliniques Universitaires Saint-Luc, 1200 Brussels, Belgium.

Kelly Cremer (K)

Department of Epidemiology and Biostatistics, Institut de Recherche Expérimentale et Clinique, Faculty of Public Health, UCLouvain, 1200 Brussels, Belgium.

Joanna Merckx (J)

Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC H3A 1A2, Canada.

Mathilde De Keukeleire (M)

Department of Epidemiology and Biostatistics, Institut de Recherche Expérimentale et Clinique, Faculty of Public Health, UCLouvain, 1200 Brussels, Belgium.

Florence Renard (F)

Office de la Naissance et de l'Enfance (ONE), 1060 Brussels, Belgium.

Nathalie Ribesse (N)

Office de la Naissance et de l'Enfance (ONE), 1060 Brussels, Belgium.

Frédéric Minner (F)

Immunology-Vaccinology Lab of the Faculty of Veterinary Medicine, ULiège, 4000 Liège, Belgium.

Jean Ruelle (J)

Pôle de Microbiologie Médicale (MBLG), UCLouvain, 1200 Brussels, Belgium.
SmartGene Services, EPFL Innovation Park, 1015 Lausanne, Switzerland.

Benoit Kabamba (B)

Department of Epidemiology and Biostatistics, Institut de Recherche Expérimentale et Clinique, Faculty of Public Health, UCLouvain, 1200 Brussels, Belgium.
Pôle de Microbiologie Médicale (MBLG), UCLouvain, 1200 Brussels, Belgium.

Hector Rodriguez-Villalobos (H)

Department of Epidemiology and Biostatistics, Institut de Recherche Expérimentale et Clinique, Faculty of Public Health, UCLouvain, 1200 Brussels, Belgium.
Department of Microbiology, Cliniques Universitaires Saint-Luc, 1200 Brussels, Belgium.

Bertrand Bearzatto (B)

Institut de Recherche Expérimentale et Clinique (IREC), Center for Applied Molecular Technologies (CTMA), UCLouvain, 1200 Brussels, Belgium.

Marie-Luce Delforge (ML)

Institut de Biologie Clinique de l'Université Libre de Bruxelles, 1070 Brussels, Belgium.

Coralie Henin (C)

Federal Testing Platform for COVID-19, Université Libre de Bruxelles, 1070 Brussels, Belgium.

Fabrice Bureau (F)

Immunology-Vaccinology Lab of the Faculty of Veterinary Medicine, ULiège, 4000 Liège, Belgium.

Laurent Gillet (L)

Immunology-Vaccinology Lab of the Faculty of Veterinary Medicine, ULiège, 4000 Liège, Belgium.

Annie Robert (A)

Department of Epidemiology and Biostatistics, Institut de Recherche Expérimentale et Clinique, Faculty of Public Health, UCLouvain, 1200 Brussels, Belgium.

Dimitri Van der Linden (D)

Pediatric Infectious Diseases, Specialized Pediatric Service, Pediatric Department, Cliniques Universitaires Saint-Luc, 1200 Brussels, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH